JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Avadomide (formerly known as CC-122) is a novel, orally available pleiotropic pathway modulator with potential with anticancer and immunomodulatory activity. It targets the protein cereblon (CRBN), a substrate receptor of the cullin ring E3 ubiquitin ligase complex CRL4CRBN. Avadomide mimics an interferon response and has antitumor activity in DLBCL (Diffuse large B-cell lymphoma). Avadomide binds CRBN and promotes the degradation of Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. As a new chemical entity and a pleiotropic pathway modifier, Avadomide has potential application in the treatment of cancer and immune disease.
References: Blood. 2015 Aug 6; 126(6):779-89.
Related CAS#: 1015474-32-4 (free base); 1398053-45-6 (HCl);
Avadomide; CC 122; CC-122; CC122
Chemical Name: 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2, 6-dione
Exact Mass: 286.1066
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!